Graspa (asparaginase)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- asparaginase
- Company
- ERYTECH Pharma S.A.
- Status
- Application withdrawn
- Therapeutic area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- EU approval
- Wed 27 Jun 2018
- Designations
- Orphan
- Application
- EMEA/H/C/004736
- ATC
- LX1XX02
- Official record
- www.ema.europa.eu
Indication
Treatment of acute lymphoblastic leukaemia
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Spectrila Authorised · Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Follow Graspa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.